Red Cell Distribution Width and Lactate Albumin Ratio as Prognostic Markers for Mortality in Sepsis and Septic Shock

Launched by TANTA UNIVERSITY · Jun 18, 2023

Keywords

ClinConnect Summary

This clinical trial is looking at two specific tests, called red cell distribution width and lactate/albumin ratio, to see if they can help predict how likely patients with sepsis and septic shock are to survive. Sepsis is a serious condition that happens when the body has a strong reaction to an infection, and septic shock is a more severe form of sepsis where blood pressure drops dangerously low. By understanding how these tests can indicate a patient's prognosis, doctors hope to improve care for those affected by these life-threatening conditions.

To participate in this study, individuals need to be between 18 and 60 years old and diagnosed with sepsis or septic shock. However, there are some people who won't be able to join, such as those who have certain blood disorders, received a blood transfusion recently, or have serious liver or kidney issues. If eligible, participants will undergo the tests being studied, and their health outcomes will be monitored to gather valuable information that could help future patients. It's important to note that the trial is not yet recruiting participants, so more details will be available soon.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • 1. Age from 18 to 60 years old.
• • 2. Clinical criteria of sepsis
• • 3. Or clinical criteria of septic shock including sepsis with persisting hypotension requiring vasopressors to maintain mean arterial pressure \> 65 mmHg and having a serum lactate level \> 2 mmol/L despite adequate volume resuscitation.
• Exclusion Criteria:
• • 1. No informed consent.
• • 2. Patient with incomplete information and data.
• • 3. The patient who received blood transfusion within 90 days before emergency admission.
• • 4. The patients who are known to have long-term conditions causing anemia like sickle cell anemia, thalassemia, iron deficiency anemia.
• • 5. Malignancy and chemotherapy during the previous 90 days.
• • 6. Patients with either hepatic dysfunction, renal failure, having any disease in which albumin should be supplemented as liver cirrhosis with ascites, nephrotic syndrome and burns.